Vaccines, treatments and tests will soon all be commercially available. But what that means for consumers' out-of-pocket costs is unclear.
Regulatory and pipeline updates from Gilead (GILD) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.
In the past 12 months, shares of healthcare company Moderna (NASDAQ: MRNA) have fallen by more than 55% (the S&P 500 is down just 4% over that stretch). Although the company has generated billions from its COVID-19 vaccine, investors are getting more concerned about what the future looks like for the company beyond just COVID. Moderna has been sitting on billions in cash that could go a long way in investing in its business or even acquiring another company to expand its reach.